Merck KGaA’s Ezmekly Secures European Approval for Pediatric and Adult Neurofibromatosis Type 1
1. Conditional Marketing Authorization by the European Commission and Clinical Value
The European Commission (EC) rendered a final decision on July 17, 2025, granting a Conditional Marketing Authorization for Ezmekly (generic name: mirdametinib). The approval targets patients of all ages—both pediatric and adult—with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). In the pivotal Phase 2b ReNeu trial, the independent central review (BICR) demonstrated an objective response rate (ORR) of 52% in the pediatric cohort (29 of 56 patients) and 41% in the adult cohort (24 of 58 patients). Tumor volume reductions were substantial, and patients reported meaningful improvements in pain and quality of life, providing the key rationale for the authorization.
2. Differentiated Positioning and Dosing Convenience Compared with Competitors
Ezmekly enters the market with a clear advantage over the only existing competitors—AstraZeneca’s and MSD’s Koselugo (generic name: selumetinib). Koselugo is approved solely for pediatric patients, leaving adults with an unmet therapeutic need. By securing an adult indication, Ezmekly addresses this gap. Moreover, unlike Koselugo, which requires food restrictions, Ezmekly can be taken with or without meals, markedly improving patient adherence. The approval also includes a 1 mg dispersible tablet formulation designed for young children who have difficulty swallowing pills, which is expected to drive strong prescribing preference in clinical practice.
3. Synergy and Financial Impact of Merck’s Acquisition of SpringWorks
Ezmekly was initially discovered at Pfizer before being spun out to SpringWorks Therapeutics. On July 1, 2025, Merck KGaA completed the acquisition of SpringWorks for approximately $3.9 billion (enterprise value $3.4 billion), adding Ezmekly to its core pipeline. This transaction follows Merck’s earlier acquisition of the desmoid tumor therapy Ogsiveo, reinforcing its leadership in rare tumor oncology. Ezmekly received U.S. FDA approval in February of this year under the brand name Gomekli, so the European authorization is expected to generate immediate incremental global revenue. Analysts project that the product could achieve up to $1 billion in worldwide sales, positioning it as a potential blockbuster.
4. Market Entry Strategy and Pricing Negotiation Challenges
Nevertheless, after obtaining conditional approval, each European health authority will conduct separate price and reimbursement (HTA) negotiations, representing a significant hurdle. As a rare‑disease therapy, Ezmekly is expected to be priced at the high end of the market, which may delay formulary inclusion in key jurisdictions such as Germany and France during cost‑effectiveness assessments. The global NF1‑PN market is projected to grow at >8 % annually, reaching roughly $1.5–$1.9 billion by 2026. Consequently, the outcome of early pricing talks will be a critical determinant of market penetration speed and initial market share. Merck is likely to leverage patient‑support programs and long‑term Phase 2b follow‑up data to accelerate reimbursement decisions.
This approval marks the first NF1‑PN therapy for adults, allowing Merck to capture the large, unmet adult market that has been limited to pediatric use of AstraZeneca’s Koselugo. By securing a conditional European authorization for Ezmekly—Merck’s key SpringWorks asset acquired for $3.9 billion—the company will immediately diversify revenue across its global rare‑disease portfolio. Over the medium to long term, the worldwide PN market is expected to expand from roughly $1.5 billion in 2026 to about $3 billion by 2033, growing at an average of 8 % per year. Ezmekly’s meal‑independent dosing and the pediatric dispersible tablet formulation position it to capture more than 40 % of the market. From a scientific and industry perspective, the MEK1/2 inhibition of the MAPK pathway demonstrated by Ezmekly provides a proof‑of‑concept for overcoming resistance to existing therapies, serving as a valuable reference for future combination regimens and potential indications in other tumor types.
Source: EMA (ema)